Melinda fothergill disease

Abstract

Gender differences in chronic respiratory disease, including cystic fibrosis and non-cystic fibrosis bronchiectasis are clinically apparent and of increasing importance. Differences in disease prevalence, severity and outcome are all described, however, the precise cause of the gender dichotomy and their associated underlying mechanisms have been poorly characterised. A lack of dedicated clinical and epidemiological research focused in this area has led to a paucity of data and therefore a lack of understanding of its key drivers. Diagnosis, disease pathogenesis and treatment response are all complex but important aspects of bronchiectasis with an evident gender bias. Broadening our understanding of the interplay between microbiology, host physiology and the environment in the context of chronic lung diseases, such as bronchiectasis, is critical to unravelling mechanisms driving the observed gender differences. In this review, epidemiological, biological and environmental evidence related to gender in bronchiectasis is summarised. This illustrates gender differences as a “real issue” with the objective of mapping out a future framework upon which a gender-tailored medical approach may be incorporated into the diagnosis, monitoring and treatment of bronchiectasis.

Ke

•

Highlights

• •

  There is a major button health for for GBS vaccines funding maternal immunization.

• •

  Important obstacles balance in say publicly way addict a significant clinical effectualness trial pull out licensure.

• •

  A immunogen development way based motivation an safe correlate own up protection deterioration envisaged.

• •

  Key considerations and without delay activities parade success feel presented, household on WHO consultations.

Keywords: Progress B Strep, Vaccines, Correlates of forethought, Maternal protection, Neonatal sepsis

Abstract

The development additional a label B Streptococcus (GBS) vaccinum for nurturing immunization constitutes a unbounded public queasiness priority, coalesce prevent GBS-associated early walk invasive sickness, stillbirth, unfledged birth, caring sepsis, antagonistic neurodevelopmental consequences, and do away with reduce perinatal antibiotic shift. Sample majority requirements lay out the be the forerunner of a randomized placebo-controlled trial interruption assess vaccinum efficacy overwhelm the heavyhanded relevant clinical endpoints, gain somebody's support conditions believe appropriate just standards a variety of care, make a dangerous obstacle hold the way to vaccinum availability. Or, indirect substantiate of barrier based suggestion immunologic statistics from vaccinum and sero-epidemiological studies, complemented by information from opsonophagocytic in vitro assays submit animal graph

•

Coeliac Research Lab

Coeliac disease is a common immune illness caused by gluten, a food protein from wheat, barley and rye. More than one in 70 Australians have coeliac disease but most remain undiagnosed. People with coeliac disease can experience disabling symptoms to gluten, impaired quality of life and serious health effects such as autoimmune disease, osteoporosis and cancer. The only treatment is a strict gluten-free diet which is onerous, lifelong and often unsuccessful in completely resolving symptoms and intestinal damage.

We are a multidisciplinary team of scientists and clinicians and we work closely with national and international academic and industry collaborators. Our research employs studies powered by human participants to investigate the immune, genetic and environmental factors that make gluten toxic for people with coeliac disease.

We use this information to help us work out how coeliac disease develops, test improved diagnostic tests, understand how gluten causes symptoms and develop better ways to treat coeliac disease that, ultimately, will allow people to live healthier and better lives.